Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent
- 13 August 2015
- journal article
- Published by Springer Nature in Tumor Biology
- Vol. 37 (1) , 1025-1033
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Perifosine – a new option in treatment of acute myeloid leukemia?Expert Opinion on Investigational Drugs, 2013
- Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylationCytotechnology, 2010
- Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple MyelomaMolecular Cancer Therapeutics, 2010
- Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's MacroglobulinemiaClinical Cancer Research, 2010
- Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia CellsCancer Research, 2008
- Addiction to Elevated Insulin-like Growth Factor I Receptor and Initial Modulation of the AKT Pathway Define the Responsiveness of Rhabdomyosarcoma to the Targeting AntibodyCancer Research, 2008
- A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trialInvestigational New Drugs, 2006
- Cyclophosphamide Dose Intensification during Induction Therapy for Intermediate-Risk Pediatric Rhabdomyosarcoma Is Feasible but Does Not Improve OutcomeClinical Cancer Research, 2004
- Regulation of TRAIL Expression by the Phosphatidylinositol 3-Kinase/Akt/GSK-3 Pathway in Human Colon Cancer CellsJournal of Biological Chemistry, 2002
- Rhabdomyosarcoma – working out the pathwaysOncogene, 1999